Type 2 Diabetes: Insulin Resistance, Beta Cell Dysfunction, and Other Metabolic and Hormonal Abnormalities

Clinical Diabetes

Volumn , Issue , 2006, Pages 21-34

  Chavez, Brian E ^a   Henry, Robert R ^a,b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77952208465     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-0273-4.50008-4     Document Type: Chapter

References (101)

1. Pirola L, Johnston AM, Van Obberghen E Modulation of insulin action. Diabetologia 2004, 47:170-184.
2. Nikoulina SE, Ciaraldi TP, Mudaliar S, et al. Potential role of GSK3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes 2000, 49:263-271.
3. Henry RR Insulin resistance: From predisposing factor to therapeutic target in type 2 diabetes. Clin Ther 2003, 25(Supp B):B47-B63.
4. Harris MI Undiagnosed NIDDM: Clinical and public health issues. Diabetes Care 1993, 16:642-652.
5. Reaven GM Pathophysiology of insulin resistance in human disease. Physiol Rev 1995, 75:473-486.
6. Edelman SV, Henry RR. Diagnosis and Management of Type 2 Diabetes, 5th ed. New York, Professional Communications, 2002.
7. Harris MI Epidemiologic studies on the pathogenesis of non-insulin-dependent diabetes mellitus (NIDDM). Clin Invest Med 1995, 18:231-239.
8. Haffner SM, Miettenen H, Gaskell SP, Stern MP Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans. Diabetes 1995, 44:1386-1391.
9. Gulli G, Ferrannini E, Stern MP, et al. The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. Diabetes 1992, 41:1575-1586.
10. Fuller JH, Keen H, Jarret RJ, et al. Haemostatic variable associated with diabetes and its complications. BMJ 1979, 2:964-966.
11. Haffner SM, Stern MP, Hazuda HP, et al. Parental history of diabetes is associated with increased cardiovascular risk factors. Arteriosclerosis 1989, 9:928-933.
12. Henry RR Type 2 diabetes care: The role of insulin-sensitizing agents and practical implications for cardiovascular disease prevention. Am J Med 1998, 105(1A):20S-26S.
13. Petersen KF, Shulman GI Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. Am J Cardiol 2002, 90:11G-18G.
14. Best JD, Judzewitsch RG, Pfeifer MA, et al. The effects of chronic sulfonylurea therapy on hepatic glucose production in non-insulin-dependent diabetes. Diabetes 1982, 31:333-338.
15. Revers RR, Fink R, Griffin J, et al. Influence of hyper-glycemia on insulin's in vivo effects in type II diabetes. J Clin Invest 1984, 73:664-672.
16. Baron AD, Schaeffer L, Shragg P, Kolterman OG Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 1987, 36:274-283.
17. Felig P, Wahren J, Hendler R Influence of maturity-onset diabetes on splanchnic glucose balance after oral glucose ingestion. Diabetes 1978, 27:121-126.
18. Nikoulina SE, Ciaraldi TP, Mudaliar S, et al. Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes 2000, 49:263-271.
19. 3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: Amelioration by rosiglitazone and exercise. Diabetes 2003, 52:1926-1934.
20. Boden G, Ray TK, Smith RH, Owen OE Carbohydrate oxidation and storage in obese non-insulin-dependent diabetic patients. Effects of improving glycemic control. Diabetes 1983, 32:982-987.
21. Baron AD, Kolterman OG, Bell J, et al. Rates of noninsulin-mediated glucose uptake are elevated in type II diabetic subjects. J Clin Invest 1985, 76:1782-1788.
22. Wallace TM, Matthews DR The assessment of insulin resistance in man. Diabet Med 2002, 19:527-534.
23. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: Insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
24. Haffner SM, D'Agostino R, Mykkanen L, et al. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: The Insulin Resistance Atherosclerosis Study. Diabetes Care 1999, 22:562-568.
25. Ferrannini E, Mari A How to measure insulin sensitivity. J Hypertens 1998, 16:895-906.
26. Laakso M How good a marker is insulin level for insulin resistance?. Am J Epidemiol 1993, 137:959-965.
27. McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Int Med 2003, 139:802-809.
28. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000, 85:2402-2410.
29. Butler AE, Janson J, Bonner-Weir S, et al. Beta cell deficit and increased beta cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52:102-110.
30. Butler AE, Janson J, Soeller WC, Butler PC Increased beta cell apoptosis prevents adaptive increase in beta cell mass in mouse model of type 2 diabetes: Evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes 2003, 52:2304-2314.
31. Janson J, Ashley RH, Harrison D, et al. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 1999, 48:491-498.
32. Ritzel RA, Butler PC Replication increases β-cell vulnerability to human islet amyloid polypeptide-induced apoptosis. Diabetes 2003, 52:1701-1708.
33. Kahn SE, Porte D The pathophysiology and genetics of type 2 diabetes mellitus. Ellenberg and Rifkin's Diabetes Mellitus 2001, 331-365. McGraw Hill, NY. 6th ed. D. Porte, R.S. Sherwin, A. Baron (Eds.).
34. Stefan N, Stumvoll M Adiponectin-its role in metabolism and beyond. Horm Metab Res 2002, 34:469-474.
35. Shapiro L, Scherer PE The crystal structure of a complement 1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol 1998, 8:335-338.
36. Statnick MA, Beavers LS, Corominola H, et al. Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. Int J Exp Diabetes Res 2000, 1:81-88.
37. Hu E, Liang P, Spiegelman BM AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996, 271:10697-10703.
38. Arita Y, Kihara S, Takahashi M, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257:79-83.
39. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectine-mia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86:1930-1935.
40. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000, 20:1595-1599.
41. Matsubara M, Maruoka S, Katayose S Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 2002, 87:2764-2769.
42. Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002, 260:57-58.
43. Spranger J, Kroke A, Mohlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003, 361:226-228.
44. Vozarova B, Stefan N, Lindsay RS, et al. Low plasma adiponectin concentrations do not predict weight gain in humans. Diabetes 2002, 51:2964-2967.
45. Kazumi T, Kawaguchi A, Sakai K, et al. Young men with high normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care 2002, 25:971-976.
46. Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: Evidence for independent roles of age and sex. Diabetologia 2003, 46:459-469.
47. Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291:1730-1737.
48. Combs TP, Wagner JA, Berger J, et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPAR-gamma agonists: A potential mechanism of insulin sensitization. Endocrinology 2002, 143:998-1007.
49. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci 2001, 98:2005-2010.
50. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty acid oxidation by activating AMP-activated protein kinase. Nat Med 2002, 8:1288-1295.
51. Berg AH, Combs TP, Du X, et al. The adipocytes-secreted protein ACRP30 enhances hepatic insulin action. Nat Med 2001, 7:947-953.
52. Wu X, Motoshima H, Mahadev K, et al. Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rate adipocytes. Diabetes 2003, 52:1355-1363.
53. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423:762-769.
54. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7:941-946.
55. Shklyaev S, Aslanidi G, Tennant M, et al. Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats. Proc Natl Acad Sci USA 2003, 100:14217-14222.
56. Combs TP, Berg AH, Obici S, et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001, 108:1875-1881.
57. Pittas AG, Joseph NA, Greenberg AS Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2004, 89:447-452.
58. Saha AK, Schwarsin AJ, Roduit R, Masse F, et al. Activation of malonyl-CoA decarboxylase in rat skeletal muscle by contraction and the AMP-activated protein kinase activator 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside. J Biol Chem 2000, 275:24279-24283.
59. Chandran M, Phillips SA, Ciaraldi T, Henry RR Adiponectin: More than just another fat cell hormone?. Diabetes Care 2003, 26:2442-2450.
60. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996, 334:292-295.
61. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372:425-432.
62. Minokoshi Y, Kim YB, Peroni OD, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002, 415:339-343.
63. Unger RH, Zhou YT, Orci L Regulation of fatty acid home-ostasis in cells: Novel role of leptin. Proc Natl Acad Sci USA 1999, 96:2327-2332.
64. Montague CT, Farooqi IS, Whitehead JP, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997, 387:903-908.
65. Farooqi IS, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroen-docrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002, 110:1093-1103.
66. Clement K, Vaisse C, Lahlou N, et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998, 392:398-401.
67. Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: A randomized, controlled, dose-escalation trial. JAMA 1999, 282:1568-1575.
68. Caro JF, Sinha MK, Kolaczynski JW, et al. Leptin: The tale of an obesity gene. Diabetes 1996, 45:1455-1462.
69. Wang MY, Lee Y, Unger RH Novel form of lipolysis induced by leptin. J Biol Chem 1999, 274:17541-17544.
70. Banks WA, Farrell CL Impaired transport of leptin across the blood-brain barrier in obesity is acquired and reversible. Am J Physiol Endocrinol Metab 2003, 285:E10-E15.
71. Bjorbaek C, El-Haschimi K, Frantz JD, Flier JS The role of SOCS-3 in leptin signaling and leptin resistance. J Biol Chem 1999, 274:30059-30065.
72. Boden G, Shulman GI Free fatty acids in obesity and type 2 diabetes: Defining their role in the development of insulin resistance and b-cell dysfunction. Eur J Clin Invest 2002, 32(S3):14-23.
73. Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002, 109:1345-1350.
74. Steppan CM, Lazar MA Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab 2002, 13:18-23.
75. McTernan PG, McTernan CL, Chetty R, et al. Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab 2002, 87:2407-2410.
76. Heilbronn LK, Rood J, Janderova L, et al. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab 2004, 89:1844-1848.
77. Moller DE Potential role of TNF-α in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2000, 11:212-217.
78. Fried SK, Bunkin DA, Greenberg AS Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: Depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998, 83:847-850.
79. Kern PA, Saghizadeh M, Ong JM, et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995, 95:2111-2119.
80. Desfaits AC, Serri O, Renier G Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-a production in NIDDM patients after gliclazide treatment. Diabetes Care 1998, 21:487-493.
81. Hotamisligil GS, Shargill NS, Spiegelman BM Adipose expression of tumor necrosis factor-a: Direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
82. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R Effects of an engineered human anti-TNF-a antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996, 45:881-885.
83. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-a, in vivo. J Clin Endocrinol Metab 1997, 82:4196-4200.
84. Bruun JM, Lihn AS, Verdich C, et al. Regulation of adiponectin by adipose tissue-derived cytokines: In vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003, 285:E527-E533.
85. Greenberg AS, McDaniel ML Identifying the links between obesity, insulin resistance and b-cell function: Potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 2002, 32(Suppl 3):24-34.
86. Hotamisligil GS, Spiegelman BM Tumor necrosis factor a: A key component of the obesity-diabetes link. Diabetes 1994, 43:1271-1278.
87. Miles PD, Romeo OM, Higo K, et al. TNF-a-induced insulin resistance in vivo and its prevention by troglitazone. Diabetes 1997, 46:1678-1683.
88. Peraldi P, Xu M, Spiegelman BM Thiazolidinediones block tumor necrosis factor-a-induced inhibition of insulin signaling. J Clin Invest 1997, 100:1863-1869.
89. Souza SC, de Vargas LM, Yamamoto MT, et al. Overexpression of perilipin A and B blocks the ability of tumor necrosis factor alpha to increase lipolysis in 3T3-L1 adipocytes. J Biol Chem 1998, 273:24665-24669.
90. Vozarova B, Weyer C, Hanson K, et al. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 2001, 9:414-417.
91. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001, 280:E745-E751.
92. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes melli-tus. JAMA 2001, 286:327-334.
93. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101:1767-1772.
94. Bastard JP, Jardel C, Bruckert E, et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000, 85:3338-3342.
95. Gan SK, Kriketos AD, Poynten AM, et al. Insulin action, regional fat, and myocyte lipid: Altered relationships with increased adiposity. Obes Res 2003, 11:1295-1305.
96. Carr DB, Utzschneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004, 53:2087-2094.
97. Machann J, Haring H, Schick F, Stumvoll M Intramyocel-lular lipids and insulin resistance. Diabetes Obes Metab 2004, 6:239-248.
98. Mori Y, Murakawa Y, Okada K, et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 1999, 22:908-912.
99. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002, 87:2784-2791.
100. Gastaldelli A, Miyazaki Y, Pettiti M, et al. Metabolic effects of visceral fat accumulation in type 2 diabetes. J Clin Endocrinol Metab 2002, 87:5098-5103.
101. Dandona P, Aljada A, Chaudhuri A, Bandyopadhyay A The potential influence of inflammation and insulin resistance on the pathogenesis and treatment of atherosclerosis-related complications in type 2 diabetes. J Clin Endocrinol Metab 2003, 88:2422-2429.